Mr. Erez Tetro reports

VVT MED SIGNS POLAND DEAL TARGETING CAD$1.42 MILLION IN SALES

VVT Med Inc. has signed a five-year exclusive definitive distribution agreement with Calment Medical Sp zoo for the commercialization of ScleroSafe in Poland, commencing Oct. 15, 2026. The agreement includes annual purchase targets representing approximately $1.4-million in aggregate potential purchases over the contractual period, based on the agreed unit pricing and an indicative exchange rate. These targets are subject to the terms of the agreement and do not constitute guaranteed revenue.

The agreement appoints Calment Medical as VVT Med's exclusive distributor and importer of ScleroSafe in Poland and provides a framework for continued commercialization, physician training and market development. The five-year term is subject to earlier termination in accordance with the agreement. Actual purchases and revenue will depend on the distributor's performance and other applicable conditions.

The new partnership marks the next phase of VVT Med's commercial activities in Poland, where the company has already established a meaningful clinical presence. Through the efforts of its previous distribution partner, more than 1,000 ScleroSafe procedures have been performed in the country to date, alongside the development of a substantial body of clinical experience and supporting evidence.

VVT Med recognizes the important contribution of its previous distributor in establishing the technology in the Polish market, supporting physician adoption and advancing clinical experience. The transition to Calment Medical is intended to build on this established foundation and support the next stage of commercial development.

"Poland is an important market for VVT Med, with a strong foundation of clinical experience and physician familiarity with ScleroSafe," said Erez Tetro, chief executive officer of VVT Med. "We are grateful to our previous distribution partner for its significant contribution to establishing our technology in the market. With Calment Medical, we look forward to building on this foundation, supporting existing physician relationships and advancing our commercial activities in Poland."

The agreement forms part of VVT Med's broader European commercialization strategy, which focuses on developing sustainable distribution partnerships, supporting physician adoption, and expanding access to its minimally invasive NT-NT technology across established and emerging markets.

About VVT Med Inc.

VVT Medical develops, manufactures and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of vein diseases, starting with varicose veins. VVT is one of the few Food and Drug Administration-cleared, standalone companies offering NT-NT varicose vein treatment technology. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease, while enabling physicians to deliver effective, efficient and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

About Calment Medical Sp zoo

Calment Medical is a Poland-based medical device distribution company headquartered in Warsaw. Under the agreement, Calment Medical will serve as VVT Med's authorized exclusive distributor and importer of ScleroSafe products in Poland, supporting their commercialization and distribution in the local market.

We seek Safe Harbor.